Biotheus’ antibody drug targets PD-L1 and VEGF, a design that’s high on drugmakers’ radars after the success of Summit ...

Keytruda is currently indicated in a variety of cancers, including classical Hodgkin lymphoma, primary mediastinal large ...

If, as ivonescimab’s victory over Keytruda suggested, PD-(L ... The main difference is BNT327 targets PD-L1 while ivonescimab ...

BioNTech said that BNT327 has the "potential to replace current checkpoint inhibitor standard of care treatments for solid ...

The acquisition would grant BioNTech full global rights to the promising bispecific antibody BNT327/PM8002, which was ...

Adding a PD-1 inhibitor to standard of care improved disease-free survival (DFS) in stage III soft-tissue sarcoma of the ...

This will be a live, interactive online event where investors are invited to ask the company questions in real-time. If ...

BioNTech is acquiring Chinese biotech Biotheus for $800 million upfront plus $150 million in milestones, gaining multiple ...